Literature DB >> 18181526

The solution and solid state stability and excipient compatibility of parthenolide in feverfew.

Ping Jin1, Shadi Madieh, Larry L Augsburger.   

Abstract

The objectives of this research were to evaluate the stability of parthenolide in feverfew solution state and powdered feverfew (solid state), and explore the compatibility between commonly used excipients and parthenolide in feverfew. Feverfew extract solution was diluted with different pH buffers to study the solution stability of parthenolide in feverfew. Powdered feverfew extract was stored under 40 degrees C/0% approximately 75% relative humidities (RH) or 31% RH/5~50 degrees C to study the influence of temperature and relative humidity on the stability of parthenolide in feverfew solid state. Binary mixtures of feverfew powered extract and different excipients were stored at 50 degrees C/ 75% RH for excipient compatibility evaluation. The degradation of parthenolide in feverfew solution appears to fit a typical first-order reaction. Parthenolide is comparatively stable when the environmental pH is in the range of 5 to 7, becoming unstable when pH is less than 3 or more than 7. Parthenolide degradation in feverfew in the solid state does not fit any obvious reaction model. Moisture content and temperature both play important roles affecting the degradation rate. After 6 months of storage, parthenolide in feverfew remains constant at 5 degrees C/31% RH. However, approximately 40% parthenolide in feverfew can be degraded if stored at 50 degrees C/31% RH. When the moisture changed from 0% to 75% RH, the degradation of parthenolide in feverfew increased from 18% to 32% after 6-month storage under 40 degrees C. Parthenolide in feverfew exhibits good compatibility with commonly used excipients under stressed conditions in a 3-week screening study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18181526      PMCID: PMC2750358          DOI: 10.1208/pt0804105

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

1.  Preparation of microspheres by the solvent evaporation technique.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-10-13       Impact factor: 15.470

2.  Direct determination of the peptide content in microspheres by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Dong Hee Na; Patrick P DeLuca; Kang Choon Lee
Journal:  Anal Chem       Date:  2004-05-01       Impact factor: 6.986

3.  Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation.

Authors:  Santos B Murty; Dong Hee Na; B C Thanoo; Patrick P DeLuca
Journal:  Int J Pharm       Date:  2005-06-13       Impact factor: 5.875

Review 4.  Biodegradable microspheres for parenteral delivery.

Authors:  V R Sinha; A Trehan
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2005       Impact factor: 4.889

5.  Preparation and characterization of a composite PLGA and poly(acryloyl hydroxyethyl starch) microsphere system for protein delivery.

Authors:  B H Woo; G Jiang; Y W Jo; P P DeLuca
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

6.  Peptide acylation by poly(alpha-hydroxy esters).

Authors:  Andrea Lucke; Josef Kiermaier; Achim Göpferich
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

7.  PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide).

Authors:  Dong Hee Na; Patrick P DeLuca
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

8.  Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation.

Authors:  Santos B Murty; B C Thanoo; Qui Wei; Patrick P DeLuca
Journal:  Int J Pharm       Date:  2005-06-13       Impact factor: 5.875

9.  Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery.

Authors:  Dong Hee Na; Santos B Murty; Kang Choon Lee; B C Thanoo; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2003-12-31       Impact factor: 3.246

10.  Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions.

Authors:  Santos B Murty; Jack Goodman; B C Thanoo; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2003-10-13       Impact factor: 3.246

View more
  16 in total

1.  Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer.

Authors:  Emilie Viennois; Bo Xiao; Saravanan Ayyadurai; Lixin Wang; Peng G Wang; Quan Zhang; Yue Chen; Didier Merlin
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

2.  Selected physical and chemical properties of Feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance.

Authors:  Ping Jin; Shadi Madieh; Larry L Augsburger
Journal:  AAPS PharmSciTech       Date:  2008-01-04       Impact factor: 3.246

3.  ACT001 modulates the NF-κB/MnSOD/ROS axis by targeting IKKβ to inhibit glioblastoma cell growth.

Authors:  Qiuying Li; Yu Sun; Bowen Liu; Jiabo Li; Xin Hao; Weizhi Ge; Xuemei Zhang; Shiqi Bao; Jianmiao Gong; Zhenhuan Jiang; Chuanjiang Qiu; Liqing Zhao; Yapu Zhao; Yue Chen; Xuejun Yang; Yahui Ding; Zhenzhou Wu
Journal:  J Mol Med (Berl)       Date:  2020-01-04       Impact factor: 4.599

4.  Preliminary Assessment of the Chemical Stability of Dried Extracts from Guazuma ulmifolia Lam. (Sterculiaceae).

Authors:  Gisely C Lopes; Renata Longhini; Paulo Victor P Dos Santos; Adriano A S Araújo; Marcos Luciano Bruschi; João Carlos P de Mello
Journal:  Int J Anal Chem       Date:  2012-01-12       Impact factor: 1.885

5.  Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo.

Authors:  Yinghong An; Wanjun Guo; Linna Li; Chengwang Xu; Dexuan Yang; Shanshan Wang; Yaxin Lu; Quan Zhang; Jiadai Zhai; Hongxia Fan; Chuanjiang Qiu; Jie Qi; Yue Chen; Shoujun Yuan
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  Epoxymicheliolide, a novelguaiane-type sesquiterpene lactone, inhibits NF‑κB/COX‑2 signaling pathways by targeting leucine 281 and leucine 25 in IKKβ in renal cell carcinoma.

Authors:  Jiabin Zhu; Jun Zhao; Zhenlong Yu; Sandeep Shrestha; Jing Song; Wenwen Liu; Wen Lan; Jinshan Xing; Shuang Liu; Chen Chen; Momo Cao; Xiuzhen Sun; Qi Wang; Xishuang Song
Journal:  Int J Oncol       Date:  2018-06-29       Impact factor: 5.650

7.  The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo.

Authors:  Ning Xu; Zhongyan Hua; Gen Ba; Simeng Zhang; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  J Exp Clin Cancer Res       Date:  2019-03-08

8.  ROS generation and autophagosome accumulation contribute to the DMAMCL-induced inhibition of glioma cell proliferation by regulating the ROS/MAPK signaling pathway and suppressing the Akt/mTOR signaling pathway.

Authors:  Yanjun Wang; Jiachen Zhang; Yihang Yang; Qian Liu; Guangming Xu; Rui Zhang; Qi Pang
Journal:  Onco Targets Ther       Date:  2019-03-07       Impact factor: 4.147

9.  Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells.

Authors:  Qing Ji; Ya-Hui Ding; Yue Sun; Yu Zhang; Hui-Er Gao; He-Nan Song; Ming Yang; Xiao-Lei Liu; Zi-Xiang Zhang; Ying-Hui Li; Ying-Dai Gao
Journal:  Oncotarget       Date:  2016-10-04

10.  Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia.

Authors:  Jing Li; Shanshan Li; Jianshuang Guo; Qiuying Li; Jing Long; Cheng Ma; Yahui Ding; Chunli Yan; Liangwei Li; Zhigang Wu; He Zhu; Keqin Kathy Li; Liuqing Wen; Quan Zhang; Qingqing Xue; Caili Zhao; Ning Liu; Ivaylo Ivanov; Ming Luo; Rimo Xi; Haibo Long; Peng George Wang; Yue Chen
Journal:  J Med Chem       Date:  2018-04-29       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.